S4068

Splitomicin

≥98% (HPLC), powder

• Synonym(e): 1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one
• Empirische Formel (Hill-System): C₁₃H₁₀O₂
• CAS-Nummer: 5690-03-9
• Molekulargewicht: 198.22
• NACRES: NA.77
• PubChem Substance ID: 24724608
• UNSPSC Code: 12352200
• MDL number: MFCD08705254
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• storage temp.: 2-8°C
• SMILES string: O=C1CCc2c(O1)ccc3ccccc23
• InChI: 1S/C13H10O2/c14-13-8-6-11-10-4-2-1-3-9(10)5-7-12(11)15-13/h1-5,7H,6,8H2
• InChI key: ISFPDBUKMJDAJH-UHFFFAOYSA-N

Beschreibung

Application

Splitomicin was used to inhibit SIRT1 in human aortic endothelial cells[1][2] and sirtuins in human breast cancer cells.[3] Mouse leukaemic monocyte macrophage cell line was treated with Splitomicin prior to cholesterol efflux studies.[4]

Biochem/physiol Actions

Sir2p (silent information regulator) and HDAC inhibitor.

Splitomicin, a derivative of β-naphthol is an inhibitor of Silent Information Regulator 2 (SIR2). It inhibits the NAD⁺-dependent deacetylase activity of Sir2 in vitro.[5] It increases the levels of cyclic AMP by inhibiting the activity of cyclic AMP phosphodiesterase, interferes with mobilization of intracellular Ca⁺² and ATP release. This results in inhibition of platelet aggregation that is effective in cardiovascular and cerebrovascular diseases.[6]

Features and Benefits

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)